GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioAdaptives Inc (OTCPK:BDPT) » Definitions » Altman Z-Score

BDPT (BioAdaptives) Altman Z-Score : -362.36 (As of Mar. 17, 2025)


View and export this data going back to 2014. Start your Free Trial

What is BioAdaptives Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -362.34 is in distress zone. This implies bankruptcy possibility in the next two years.

BioAdaptives has a Altman Z-Score of -362.36, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for BioAdaptives's Altman Z-Score or its related term are showing as below:

BDPT' s Altman Z-Score Range Over the Past 10 Years
Min: -1847.59   Med: -271.07   Max: -22.8
Current: -362.34

During the past 9 years, BioAdaptives's highest Altman Z-Score was -22.80. The lowest was -1847.59. And the median was -271.07.


BioAdaptives Altman Z-Score Historical Data

The historical data trend for BioAdaptives's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAdaptives Altman Z-Score Chart

BioAdaptives Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only -322.90 -605.87 -88.65 -386.47 -147.42

BioAdaptives Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.56 -147.42 -271.07 -1,847.59 -362.33

Competitive Comparison of BioAdaptives's Altman Z-Score

For the Packaged Foods subindustry, BioAdaptives's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAdaptives's Altman Z-Score Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where BioAdaptives's Altman Z-Score falls into.



BioAdaptives Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

BioAdaptives's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-39.2609+1.4*-191.1304+3.3*-14.6522+0.6*0.4212+1.0*0.4348
=-362.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was $0.05 Mil.
Total Current Assets was $0.05 Mil.
Total Current Liabilities was $1.85 Mil.
Retained Earnings was $-8.79 Mil.
Pre-Tax Income was -0.038 + -0.183 + -0.307 + -0.268 = $-0.80 Mil.
Interest Expense was -0.01 + -0.018 + -0.055 + -0.039 = $-0.12 Mil.
Revenue was 0 + 0.001 + 0.012 + 0.007 = $0.02 Mil.
Market Cap (Today) was $0.78 Mil.
Total Liabilities was $1.85 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.046 - 1.852)/0.046
=-39.2609

X2=Retained Earnings/Total Assets
=-8.792/0.046
=-191.1304

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-0.796 - -0.122)/0.046
=-14.6522

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=0.780/1.852
=0.4212

X5=Revenue/Total Assets
=0.02/0.046
=0.4348

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

BioAdaptives has a Altman Z-Score of -362.36 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


BioAdaptives  (OTCPK:BDPT) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


BioAdaptives Altman Z-Score Related Terms

Thank you for viewing the detailed overview of BioAdaptives's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAdaptives Business Description

Traded in Other Exchanges
N/A
Address
2620 Regatta Drive, Suite 102, Las Vegas, NV, USA, 89128
BioAdaptives Inc is engaged in investigating, marketing and distributing natural plant- and algal-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. The human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. Its product lines include PluriPain, PrimiLungs, SleepEZ, MindNMemory, Cell Rejuven and ProteinNMore.
Executives
Richard Chiang other: Previous Officer and Director 460 BRANNAN STREET SUITE 78064, SAN FRANCISCO CA 94107
Barry Epling director 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Ferris Holding Inc. 10 percent owner 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128
Gerald Epling director, officer: Pres, CEO, Secretary, CFO 2251 NORTH RAMPART BLVD., #182, LAS VEGAS NV 89128

BioAdaptives Headlines

From GuruFocus